The invention provides application of a sesquiterpene compound 6-OAP in preparation of STAT3 inhibitors and in treatment of diseases unusually relevant to STAT3, and a pharmaceutical composition for treatment of diseases unusually relevant to STAT3. The pharmaceutical composition contains 6-OAP. 6-OAP can quickly combine with STAT3, can significantly inhibit phosphorylation of STAT3 in a cell and animal tumor-bearing model and significantly inhibit the activity of STAT3 induced by inflammatory factors, and has no significant toxic and side effect on other normal tissues. With the advantages of proper dose, significant curative effect, definite action target, and low toxic and side effects, etc., the 6-OAP has wide anticancer and anti-inflammatory application prospects clinically.
The invention discloses novel application of desloratadine and a pharmacologically acceptable salt of desloratadine in preparing a drug for treating alzheimer's disease and novel application in preparing a drug for treating and protecting nerve cells and / or increasing Abeta, clearing and / or inhibiting Tau proteinphosphorylation related neurodegenerative diseases such as Parkinson's disease. According to a great number of experiments, the desloratadine and the pharmacologically acceptable salt of desloratadine have obvious effects of protecting nerve tool cells SH-SY5Y from STZ injuries, promoting removal of exogenous Abeta by SH-SY5Y cells, and also can obviously inhibit phosphorylation level of Tau proteins in the SH-SY5Y cells. Therefore, desloratadine and the pharmacologically acceptable salt of desloratadine can be used for treating the alzheimer's disease and nerve cell damages and / or Abeta and / or Tau protein related diseases, and is of significant meaning in developing novel clinical applicability of desloratadine.
The present invention discloses an Erk signal pathway inhibitor, and belongs to the field of cellbiology. According to the present invention, the Mycobacteriumtuberculosissecretory protein Mce3E capable of inhibiting the Erk1 / 2 signal pathway is firstly determined, and the Mce3E achieves the inhibition on the Erk1 / 2 signal pathway through spatial regulation on the Erk1 / 2 protein; the results of the present invention can provide new tools and ideas for the clinical treatment of various diseases, especially provide wide prospects in the fields of development, clinical application and the like of anti-tumor drugs and other drugs, and can further be directly used in the scientific research field or be used for guide the development of Erk1 / 2 inhibitor; and the result further provides the important theoretical significance for finding of the new drug target and screening of the new drug.